<DOC>
	<DOCNO>NCT02549404</DOCNO>
	<brief_summary>This long-term study design evaluate safety efficacy KHK7580 orally administer daily 52 week patient secondary hyperparathyroidism receive hemodialysis .</brief_summary>
	<brief_title>Phase 3 Study KHK7580</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Personally submit write voluntary inform consent participate study Stable chronic renal disease treat hemodialysis 3 time weekly least 12 week screen Intact PTH level &gt; 240 pg/ml screening ( except subject receive cinacalcet hydrochloride screen ) Change dose dose regimen cinacalcet hydrochloride activate vitamin D drug derivative , phosphate binder , calcium preparation within 2 week screen ; start treatment drug within 2 week screen ; Parathyroidectomy and/or parathyroid intervention within 24 week screen ; Severe heart disease ; Severe hepatic dysfunction ; Uncontrolled hypertension and/or diabetes ; Treatment investigational product ( drug medical device ) clinical study study equivalent clinical study within 12 week screen ; Primary hyperparathyroidism ; Other condition unfit participation study discretion investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>